The show that helps you maximize your wealth by turning complex financial situations into actionable advice. On Your Money. Your Mission., we answer the questions you’ve been asking about -- financial planning, investing, retirement and everything in between. Whether you’re navigating the complexities of the market or looking for the best ways to save or spend your money, tune in to hear from experienced financial advisors with JFG. Walk away from each episode with savvy tips and financial t ...
…
continue reading
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
Theralase Technologies CEO Roger DuMoulin-White Provides Update on Bladder Cancer Clinical Study
MP3•Jakson koti
Manage episode 444031432 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share updates on the company's ongoing Phase II registration study for its lead drug, Ruvidar, used in combination with the TLC-3200 Medical Laser System. The study is focused on treating Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) in both Canada and the United States. The clinical trial, a single-arm, open-label study, follows FDA guidelines and involves the intravesical installation of reconstituted Ruvidar followed by activation with the TLC-3200 Medical Laser. So far, 75 patients have been enrolled and have undergone the primary study procedure. The interim analysis results are promising, showing a 60.3% Complete Response (CR) rate at any point in time, which includes 37 patients achieving CR at 90 days, 3 at 180 days, and 1 at 270 days. For the secondary objective, a CR of 26.5% was achieved at 450 days. While these results are encouraging, DuMoulin-White emphasized that the data is still interim, as the clinical study is ongoing, and more data is expected as the trial progresses. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 jaksoa
MP3•Jakson koti
Manage episode 444031432 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share updates on the company's ongoing Phase II registration study for its lead drug, Ruvidar, used in combination with the TLC-3200 Medical Laser System. The study is focused on treating Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) in both Canada and the United States. The clinical trial, a single-arm, open-label study, follows FDA guidelines and involves the intravesical installation of reconstituted Ruvidar followed by activation with the TLC-3200 Medical Laser. So far, 75 patients have been enrolled and have undergone the primary study procedure. The interim analysis results are promising, showing a 60.3% Complete Response (CR) rate at any point in time, which includes 37 patients achieving CR at 90 days, 3 at 180 days, and 1 at 270 days. For the secondary objective, a CR of 26.5% was achieved at 450 days. While these results are encouraging, DuMoulin-White emphasized that the data is still interim, as the clinical study is ongoing, and more data is expected as the trial progresses. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
609 jaksoa
All episodes
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.